文献库搜索 | GeneLibs

Jo(S),Shim(WC),Park(S),Kweon(T),Ryu(WJ),Hw... Mol Ther Oncol 2026-06-18

...BRCA1-deficient tumors, and further investigation of responses to DNA-damaging agents, particularly platinum-based chemo...

Abujamous(L),Razali(R),Al-Thawadi(H) Biomol Biomed 2026-06-16

...BRCA1 VUS. We analyzed 626 BRCA1 variants from ClinVar, comprising 608 missense, 15 splice-altering, and 3 nonsense vari...

Kummar(S),Song(Z),Reiss(KA),Ford(JM),Chen(... JCO Precis Oncol 2026-06-00

...BRCA1/2. In this trial, we further evaluated adavosertib in patients with PV in BRCA1/2 solid tumors. Eligible patients ...

Zabarsky-Shasha(G),Raitses-Gurevich(M),Sto... Hum Pathol 2026-06-17

Pancreatic ductal adenocarcinoma arising in carriers of germline BRCA1 or BRCA2 mutations represents a molecularly defin...

Wang(C),Cheng(X),Liu(Z),Wang(Y),Gao(Y),Liu(Y) Life Sci 2026-09-15

...BRCA1-associated RING domain protein 1 (BARD1), a DNA damage response protein, in GBM and its potential link to liquid-l...

Sun(C),Luo(H),Zhang(J) RNA 2026-08-17

...BRCA1-deficient tumors remains unclear. Here, transcriptomic profiling of BRCA1-mutant breast cancer identified HORMAD1 ...

Nikolaeva(M),Bellomo(J),Gönel(M),Stumpo(V)... Int J Cancer 2026-06-18

...BRCA1/2 for breast cancer and BRAF, KIT, NRAS among others for melanoma. Adjustment of systemic therapies based on BM mo...

Gu(W),Xu(C),Fu(J),Lei(H),Khan(NU),Lei(R),C... Front Oncol None

...BRCA1/2 P/LP carrier probability, which was the large high-risk clinical cohort with information of BRCA1/2 variants and...

Huang(Z),Abbas(M),Hussain(A),Long(M),Muzam... Front Cell Dev Biol None

...BRCA1/2, TP53, ATM, and DNMT3A with pleiotropic roles. Mechanistically, defects in pathways like homologous recombinatio...

Qin(S),An(J),Qiao(W),Zhichao(X),Siyao(T),S... Biomed Pharmacother 2026-08-00

...BRCA1/2 reversion mutations, 53BP1/Shieldin-mediated HR restoration, replication fork stabilization, Polθ-mediated theta...